Advertisement
Table 1 Characteristics of core strategy
| Category | n = 1427 |
|---|---|
| Status of antimicrobial use n (%) | 573 (40.2) |
| Carbapenems use | 288 (20.2) |
| 3,4-Generation Cephalosporins, Quinolones | 149 (10.4) |
| >14 inpatient days | |
| Glycopeptides use | 136 (9.5) |
| Isolation of pathogenic microorganisms n (%) | 854 (59.8) |
| Blood culture - positive | 360 (25.2) |
| MRSA | 334 (23.4) |
| ESBLs | 73 (5.1) |
| P. aeruginosa | 71 (5.0) |
| Acinetobacter baumannii | 16 (1.1) |
